Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Nephroprotection by antihypertensive agents

R E Schmieder¹

¹Department of Medicine IV/Nephrology, University of Erlangen-Nürnberg, Germany.

Journal of Cardiovascular Pharmacology

|January 1, 1994

Summary

Controlling high blood pressure slows kidney failure progression. Angiotensin-converting enzyme (ACE) inhibitors may offer superior kidney protection compared to other antihypertensive drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.

Cardiovascular diabetology·2021

Same author

[Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on the management of arterial hypertension].

Der Internist·2019

Same author

[European guidelines for the management of arterial hypertension 2018-what has changed?]

Der Internist·2019

Same author

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.

Cardiovascular diabetology·2018

Same author

Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country.

The European journal of health economics : HEPAC : health economics in prevention and care·2015

Same author

Low resting heart rates are associated with new-onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies.

Journal of internal medicine·2015

Area of Science:

Nephrology
Cardiology
Pharmacology

Background:

Arterial hypertension accelerates renal failure.
Blood pressure reduction is proven to slow kidney disease progression.
Ambulatory blood pressure monitoring is key for 24-h blood pressure control, aiming below 140/90 mm Hg.

Purpose of the Study:

To evaluate the impact of antihypertensive therapy on renal failure progression.
To compare the nephroprotective effects of different antihypertensive agents, particularly ACE inhibitors.

Main Methods:

Assessing renal failure progression using renal plasma flow and glomerular filtration rate.
Analyzing the influence of antihypertensive agents on renal hemodynamics and intraglomerular pressure.
Reviewing animal and human studies on ACE inhibitors and calcium antagonists in renal disease.

Main Results:

Systemic antihypertensive therapy slows renal failure progression regardless of etiology.
ACE inhibitors increase renal blood flow and show potential in preventing glomerulosclerosis.
ACE inhibitors demonstrated a lesser reduction in glomerular filtration rate compared to other antihypertensives.

Conclusions:

Systemic antihypertensive therapy is crucial for slowing renal failure progression.
ACE inhibitors show promise as superior agents for kidney protection in hypertensive patients.
Further research is needed to clarify the antiproliferative mechanisms of ACE inhibitors in renal protection.

Related Experiment Videos